$MRK News

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck’s Q3 Results on Oct. 29

Can Merck (MRK) Stay Undervalued If Cash Flow Keeps Growing?

Oncologists Cheer Melanoma Data

Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug?

Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’

Moderna And Merck Cancer Vaccine Cuts Melanoma Death Risk By 42%

Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful

Merck (MRK) Wins EU Approval For KEYTRUDA Plus Padcev In Bladder Cancer

Merck Won a Wider EU Bladder Cancer Label for Keytruda. Here’s What Its ESMO Data Needs to Show

MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes

Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium

Moderna Stock Plummets 25% After Cancer-Vaccine Data Leak

Moderna, Merck Shares Fall After Possible Melanoma Data Leak

Pfizer’s High Dividend Yield May Be a Warning. Here’s How Merck Compares

FDA Grants Traditional Approval For Pembrolizumab Or Pembrolizumab And Berahyaluronidase alfa-pmph For Unresectable Or Metastatic TMB-H Solid Tumors With Updated Indication

Merck And Moderna Report Phase 3 Melanoma Trial Results For Personalized mRNA Cancer Therapy; Intismeran Plus KEYTRUDA Cuts Melanoma Recurrence Or Death Risk By 42%

Moderna shares plunge on partial leak of cancer vaccine data

Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline

Merck (MRK) Laps the Stock Market: Here's Why